Poster-Disease-modifying Therapy
October 25, 2021
Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening Early 3 Months Post Approval Data
Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...
Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data
Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...